* Eiger BioPharmaceuticals announces sale of non-strategic assets to Theragene Pharmaceuticals

* Eiger BioPharmaceuticals Inc - financial terms of agreement include a total upfront of $3.1 million in payments from Theragene to Eiger

* Eiger BioPharmaceuticals Inc - additional financial terms are not being disclosed

* Eiger BioPharmaceuticals Inc - Theragene has committed to repurchase $1.35 million of common stock paid to Eiger upon closing of a financing raise of $4 million or more

* Eiger BioPharmaceuticals Inc - financial terms of agreement include expense reimbursement in addition to $2.85 million in Theragene common stock

* Eiger BioPharmaceuticals Inc - financial terms of agreement include pre-specified clinical, regulatory milestones totaling $15 million, royalties on net sales, sublicensing milestone fees Source text for Eikon: Further company coverage: